Clinical trial NCT06322927: PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma
Official title: PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Multiple Myeloma
Keywords: Patient Experience
Treatment Preference
Qualitative Study
Patient Interviews
Lead sponsor: The Christie NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: CellCentric Ltd.
First posted: 2024-03-21
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with multiple myeloma who have received at least five lines of treatment.

Brief summary: This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to them when making treatment decisions.

Detailed description: People can receive many lines of treatment for multiple myeloma. We would like to understand more about the experiences of people being treated for multiple myeloma including what matters most to them when considering treatment options, how their experiences have differed with different treatments and if they have any treatment preferences. Patients at The Christie who have received five or more lines of treatment for Multiple Myeloma will be eligible to take part in this study. They will be asked to participate in an interview which should take approximately 30 minutes to an hour. During the interview they will be asked questions regarding their experiences and preference for treatment. Interviews will be conducted either in person or over the phone depending on patient preference. The interviews will be recorded by the research team using a Dictaphone and transcribed by an external transcription service called 1st Class Secretarial. The transcripts of all participant interviews will be reviewed by members of the research team and experiences will be identified and described.

Eligibility criteria: Inclusion Criteria:

1. Participants with confirmed MM (per standard disease specific diagnostic criteria)
2. Participants must have received ≥ 5 lines of treatment for MM and fit into one of the below treatment categories:

   1. Subset 1- Participants must have received an oral anti-cancer therapy and a bi-specific antibody treatment.
   2. Subset 2- Participants must have received an oral anti-cancer therapy and if they have not had a bi-specific antibody treatment, they must have received at least one IV therapy.
3. Aged 18 years of age or over
4. Able to provide informed consent
5. Able to communicate in English

Exclusion Criteria:

1. Aged under 18
2. Unable to understand and communicate in the English language
3. Unable to provide written informed consent

Primary outcomes:
measure: Patient Experience and Preference
timeFrame: 30-60 minutes
Secondary outcomes:
measure: Treatment and Preference Differences
timeFrame: 30-60 minutes
Other outcomes:
Locations:
city: Manchester
country: United Kingdom
facility: The Christie NHS Foundation Trust
state: Greater Manchester
Study officials:
affiliation: The Christie NHS Foundation Trust
name: Sally Taylor, PhD
role: PRINCIPAL_INVESTIGATOR
References: